Doctor of Osteopathy Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Troy Virgil Taduran

Neuromusculoskeletal Medicine, Sports Medicine Tucson, AZ Doctor of Osteopathy

NPI 1760697890 CMS profile 555626

395 N Silverbell Rd, 101, Tucson, AZ 85745

Open in the dashboard

General payments

$634

32 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Troy Virgil Taduran of Tucson, AZ is reported in the CMS Open Payments database as having received $634 across 32 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 69th percentile of Neuromusculoskeletal Medicine, Sports Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

6 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $33 1
2024 General $63 3
2023 General $36 2
2021 General $346 17
2020 General $106 6
2019 General $50 3

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Troy Virgil Taduran
  • Neuromusculoskeletal Medicine, Sports Medicine median
  • Middle half of Neuromusculoskeletal Medicine, Sports Medicine
  • National median

In program year 2025, general payments to Troy Virgil Taduran were reported at $33. Among 69 Neuromusculoskeletal Medicine, Sports Medicine profiles paid that year, the median was $125 and the middle half received between $37 and $473.

Show as a table
Year Troy Virgil Taduran Neuromusculoskeletal Medicine, Sports Medicine median Middle half National median
2019 $50 $152 $43–$474 $163
2020 $106 $113 $31–$725 $114
2021 $346 $167 $50–$469 $132
2022 $0 $132 $46–$572 $149
2023 $36 $109 $39–$366 $160
2024 $63 $115 $37–$321 $164
2025 $33 $125 $37–$473 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Flexion Therapeutics, Inc. $389 17 payments
  2. Horizon Therapeutics plc $53 4 payments
  3. DePuy Synthes Sales Inc. $43 2 payments
  4. KCI USA, Inc $42 2 payments
  5. Bioventus LLC $33 1 payment
  6. Orthofix Medical, Inc. $31 4 payments
  7. IBSA Pharma Inc. $21 1 payment
  8. Ferring Pharmaceuticals Inc. $20 1 payment

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $634 32 payments
Products named General payments · program years 2019–2025
  1. Zilretta $389 17 payments
  2. MONOVISC $43 2 payments
  3. PREVENA $42 2 payments
  4. PENNSAID $40 3 payments
  5. DUROLANE $33 1 payment
  6. 3M Skin and Nasal Antiseptic $27 1 payment
  7. Tirosint Endocrinology $21 1 payment
  8. Licart $21 1 payment
  9. TIROSINT Endocrinology $21 1 payment
  10. EUFLEXXA $20 1 payment
  11. Other $60 6 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 2 drugs

Part D claims

73

Median for Sports Medicine: 144

Drug cost

$138

Median for Sports Medicine: $1,027

Branded share of claims

26%

Median for Sports Medicine: 0%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Tramadol Hcl Generic 54 $116
Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen Brand 19 $22

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 1,691 Part D prescribers listed as Sports Medicine; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 33 billing codes

Paid by Medicare

$514,090

Of which drugs: $402,517

Medicare patients

685

Average age 75

Services billed

10,361

442 women, 243 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
Arthritis 75%
High blood pressure 62%
Ischemic heart disease 20%
Chronic kidney disease 20%
Diabetes 19%
Depression 17%
Atrial fibrillation 16%
Osteoporosis 16%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Hyaluronan or derivative, monovisc, for intra-articular injection, per dose J7327 Office 374 668 $357,448
Hyaluronan or derivative, trivisc, for intra-articular injection, 1 mg J7329 Office 34 4,975 $27,974
Hyaluronan or derivative, durolane, for intra-articular injection, 1 mg J7318 Office 12 960 $3,887
Injection, triamcinolone acetonide, not otherwise specified, 10 mg J3301 Office 75 527 $393
Injection, methylprednisolone acetate, 1 mg J1010 Office 14 640 $65

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

32 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Neuromusculoskeletal Medicine, Sports Medicine in Arizona

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record